Pregnenolone,
does it really help with Improved memory, cognition, and brain aging in healthy middle-aged and older adults?
research showsPregnenolone is rated D for improving memory, cognition, or brain aging in healthy middle-aged and older adults. In a double-blind crossover study of 17 healthy volunteers, four weeks of treatment had no significant effect on memory, mood, or sleep. Because a direct human trial exists, the grade is D rather than unknown. An eight-week randomized trial in 120 people with schizophrenia also found no improvement over placebo in the cognitive composite, and no long-term healthy-aging trial tested imaging, dementia incidence, or cognitive decline. The score is 22 points; hormone-precursor status and long-term safety gaps remain separate concerns.
ads claimMechanistic phrases such as mother of all steroid hormones, neurosteroid, and improved memory in animals are converted into clinical claims of better memory and prevention of brain aging. Hormone changes and preclinical signals are not evidence of long-term cognitive protection.
Useful facts when choosing a product
- Pregnenolone is a hormone precursor that can enter pathways producing progesterone, DHEA, and multiple other steroids, so it should not be treated like an ordinary nutrient.
- Supplement dose and purity can vary by product, and findings from research doses ranging from 15 to 500 mg cannot be transferred automatically to an arbitrary commercial product.
- Short small trials generally reported tolerability, but evidence is inadequate to judge long-term hormonal, cardiovascular, hepatic, mood-related, or cancer-related safety in healthy middle-aged and older adults.
- People with hormone-sensitive conditions, pregnancy or breastfeeding, liver disease, psychiatric symptoms, or use of hormonal, steroid, or antiseizure medicines should consult a clinician before self-treatment.
What the research actually shows
In the Meieran study, 17 normal volunteers took pregnenolone and placebo for four weeks each, separated by a four-week washout, in a within-participant double-blind crossover design. Pregnenolone alone had no significant memory effect. The Marx trial randomized 120 people with schizophrenia to pregnenolone or placebo for eight weeks; some functional-capacity measures improved, but the primary MCCB cognitive composite did not. The Ritsner study assigned 58 people with schizophrenia or schizoaffective disorder to 30 mg, 200 mg, DHEA, or placebo and reported some attention and working-memory improvement at 30 mg, while 200 mg did not differ. No study was identified that measured long-term cognitive decline, brain-imaging aging, or dementia incidence in healthy older adults.
Why this is classified as D (22)
A direct controlled study in healthy volunteers exists, so the unknown grade for absent human literature does not apply. That 17-person trial was null for memory, and a larger schizophrenia trial was also null for its cognitive composite. Positive low-dose subscales in a disease population are indirect, and long-term clinical outcomes of brain aging in healthy older adults are absent. Direct null evidence combined with predominantly preclinical and indirect support gives D with 22 points. Unknown long-term safety remains separate.
Counterpoint. The available studies are small, so this is not a final conclusion that every dose is harmful or can never work. An independent, adequately powered trial in healthy middle-aged and older adults would need sufficient duration, a preregistered cognitive primary endpoint, and brain imaging or dementia incidence.
Rejudgment record. New verdict — Reflected the direct double-blind crossover study in 17 healthy volunteers that was null for memory and the null cognitive composite in a 120-person schizophrenia trial, restricted disease-population subscales and preclinical mechanisms as indirect evidence, and accounted for the absence of long-term brain-aging outcomes in healthy older adults
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Improved memory in healthy middle-aged and older adults | D | A direct crossover study in 17 healthy volunteers indexed as including middle-aged and older adults found no memory benefit. |
| Improved overall cognition in healthy middle-aged and older adults | D | Direct healthy-human evidence is small and null, and the cognitive composite was also null in a larger disease-population trial. |
| Slowing progression of brain aging | ? | No human trial was found that directly tested long-term cognitive decline, brain-imaging aging, or dementia incidence in healthy older adults. |
| Preclinical neurosteroid mechanisms establishing human efficacy | F | Mechanistic and animal evidence cannot establish human clinical efficacy. |
Cross-check — Codex and Claude
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Meieran SE et al. 2004 | Within-participant double-blind placebo-controlled crossover trial | 17 | United States academic research with no industry sponsorship reported in the abstract | Memory, mood, sleep, subjective well-being, and tolerability | Four weeks of pregnenolone alone had no significant effect on memory or other behavioral outcomes. | Key direct null healthy-human trial |
| Marx CE et al. 2014 | Eight-week randomized placebo-controlled proof-of-concept trial | 111 | United States and Singapore public and academic support | MCCB cognitive composite, functional capacity, and negative symptoms | Some functional-capacity measures improved, but the cognitive composite did not improve significantly versus placebo. | Larger indirect null cognitive trial |
| Ritsner MS et al. 2010 | Eight-week double-blind randomized placebo-controlled dose-parallel trial | 58 | Academic research; full text is needed for detailed conflicts | Symptoms, attention, working memory, function, and tolerability | The 30-mg group improved on some attention and working-memory measures, while 200 mg did not differ from placebo, showing no dose consistency. | Indirect small conflicting evidence |
Receipt — 3 References
All 3 cited sources were verified for existence at the original page (as of 2026-07-20).
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-20 · Corrections: none
Cite this verdict
[Chamgap] Pregnenolone x improved memory, cognition, and brain aging in healthy middle-aged and older adults — Evidence Grade D·22. 3 cited sources checked. Source: https://chamgap.com/en/verdicts/cognition/pregnenolone-healthy-middle-older-adults-memory-cognition-brain-aging/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.